Evidence map›Paper›PMID 33723251›Full record

ArticleCell death discovery2021

Plasma IL-6 levels following corticosteroid therapy as an indicator of ICU length of stay in critically ill COVID-19 patients.

Samir Awasthi, Tyler Wagner, A J Venkatakrishnan, Arjun Puranik, Matthew Hurchik, Vineet Agarwal, Ian Conrad, Christian Kirkup, Raman Arunachalam, John O'Horo and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 2 pooled it
2.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 4 institutions in 2 countries.

Samir Awasthi *nference, Cambridge, MA, 02142, USA.
Tyler Wagner *nference, Cambridge, MA, 02142, USA.
A J Venkatakrishnannference, Cambridge, MA, 02142, USA.
Arjun Puraniknference, Cambridge, MA, 02142, USA.
Matthew Hurchiknference, Cambridge, MA, 02142, USA.
Vineet Agarwalnference, Cambridge, MA, 02142, USA.ORCID http://orcid.org/0000-0001-6235-5577
Ian Conradnference, Cambridge, MA, 02142, USA.
Christian Kirkupnference, Cambridge, MA, 02142, USA.
Raman Arunachalamnference Labs, Bangalore, India.
John O'HoroMayo Clinic, Rochester, MN, 55905, USA.ORCID http://orcid.org/0000-0002-0880-4498
Walter KremersMayo Clinic, Rochester, MN, 55905, USA.
Rahul KashyapMayo Clinic, Rochester, MN, 55905, USA.
William MoriceMayo Clinic, Rochester, MN, 55905, USA.
John HalamkaMayo Clinic, Rochester, MN, 55905, USA.
Amy W WilliamsMayo Clinic, Rochester, MN, 55905, USA.
William A FaubionMayo Clinic, Rochester, MN, 55905, USA.
Andrew D BadleyMayo Clinic, Rochester, MN, 55905, USA.ORCID http://orcid.org/0000-0001-7796-7680
Gregory J GoresMayo Clinic, Rochester, MN, 55905, USA.
Venky Soundararajannference, Cambridge, MA, 02142, USA. venky@nference.net.ORCID http://orcid.org/0000-0001-7434-9211
Nference (United States) · USMayo Clinic in Arizona · USMayo Clinic · USNference (India) · IN

Funding

Evaluating the role of the novel apoptosis inhibitor TRAILshort, in maintaining HIV persistence.R01AI120698 · NIAID · MAYO CLINIC ROCHESTER · PI BADLEY, ANDREW D · 2015 to 2019
$2.5M
Evaluating the role of the novel apoptosis inhibitor TRAILshort, in maintaining HIV persistenceR56AI120698 · NIAID · MAYO CLINIC ROCHESTER · PI BADLEY, ANDREW D · 2021 to 2021
$607k
NIAID NIH HHS R01 AI120698NIAID NIH HHS R56 AI120698
6 · The paper itself

Abstract

Intensive care unit (ICU) admissions and mortality in severe COVID-19 patients are driven by "cytokine storms" and acute respiratory distress syndrome (ARDS). Interim clinical trial results suggest that the corticosteroid dexamethasone displays better 28-day survival in severe COVID-19 patients requiring ventilation or oxygen. In this study, 10 out of 16 patients (62.5%) that had an average plasma IL-6 value over 10 pg/mL post administration of corticosteroids also had worse outcomes (i.e., ICU stay >15 days or death), compared to 8 out of 41 patients (19.5%) who did not receive corticosteroids (p-value = 0.0024). Given this potential association between post-corticosteroid IL-6 levels and COVID-19 severity, we hypothesized that the glucocorticoid receptor (GR or NR3C1) may be coupled to IL-6 expression in specific cell types that govern cytokine release syndrome (CRS). Examining single-cell RNA-seq data from BALF of severe COVID-19 patients and nearly 2 million cells from a pan-tissue scan shows that alveolar macrophages, smooth muscle cells, and endothelial cells co-express NR3C1 and IL-6, motivating future studies on the links between the regulation of NR3C1 function and IL-6 levels.

Identifiers

PMID33723251
PMCPMC7958587
OpenAlexW3138901698

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.